Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation.
During the course of extracorporeal circulation, leukocyte aggregation is known to occur in some patients. This is attributed to complement activation and release of the chemotactic factor C5a. We investigated the effect of heparin on in vitro complement induced aggregation of polymorphonuclear leukocytes (PMNAGG), since most patients undergo heparinization during the extracorporeal circulation. Our results indicate that sub-aggregating concentrations of zymosan-activated serum (ZAS) enhance heparin-induced PMNAGG and that sub-aggregating amounts of heparin increase the aggregation induced by ZAS. Heat inactivation of the serum prior to zymosan activation abrogated the aggregating activity of the ZAS. Furthermore, the combined ZAS and heparin-induced PMNAGG was partially inhibited by specific antibodies to C5a but not to C3a. Therefore, we suggest that heparin and C5a may have a synergistic effect on the aggregation of polymorphonuclear leukocytes. These data might be relevant to situations in which patients are subjected to extracorporeal circulation.
Berliner
S
S
Department of Internal Medicine D, Beilinson Medical Center, Rehovot, Israel.
Fishelson
Z
Z
Wasserman
L
L
Pinkhas
J
J
Aronson
M
M
D002449:Cell Aggregation / Q000187:drug effects; D003167:Complement Activation; D003182:Complement C5 / Q000502:physiology; D015936:Complement C5a; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D009504:Neutrophils / Q000502:physiology*; D015054:Zymosan / Q000494:pharmacology
D003182:Complement C5; D015936:Complement C5a; D006493:Heparin; D015054:Zymosan